In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

Mark H. Ebell

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{4b01c0f43392411a9885e90980456349,

title = "In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality",

author = "Ebell, {Mark H.}",

year = "2016",

month = mar,

day = "1",

language = "English (US)",

volume = "93",

pages = "410",

journal = "American family physician",

issn = "0002-838X",

publisher = "American Academy of Family Physicians",

number = "5",

}

TY - JOUR

T1 - In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

AU - Ebell, Mark H.

PY - 2016/3/1

Y1 - 2016/3/1

UR - http://www.scopus.com/inward/record.url?scp=84959449270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959449270&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 26926979

AN - SCOPUS:84959449270

SN - 0002-838X

VL - 93

SP - 410

JO - American family physician

JF - American family physician

IS - 5

ER -